Sanjay Gupta to Join Everyday Health
Dr. Sanjay Gupta will join Everyday Health to deliver health and medical news. MedPage Today, a company website that targets physicians, will be the exclusive home of The Gupta Guide, a daily digest of the news doctors need every day. It will provide a digital platform for Gupta to complement the one he has already established on television through his continuing affiliations with CNN and CBS News. Gupta, one of the most trusted voices on health issues in America today, is a neurosurgeon, an assistant professor of neurosurgery at Emory University School of Medicine, and associate chief of the neurosurgery service at Grady Memorial Hospital in Atlanta. His books Chasing Life and Cheating Death were New York Times and national bestsellers. In January 2011, he was named “one of the 10 most influential celebrities” by Forbes magazine. “This partnership marks a watershed moment for Everyday Health,” states Ben Wolin, CEO and Founder.
AstraZeneca’s Global Appointment
Marc Dunoyer will join AstraZeneca in the newly created role of Executive Vice President, Global Portfolio & Product Strategy. He will be responsible for driving business strategy, including business development, mergers and acquisitions, and portfolio and product strategies. “Marc is a first-rate leader with a proven track record in driving business growth and he brings to AstraZeneca a wealth of international operating experience—in particular in the important Asia region—combined with outstanding strategic skills,” says Pascal Soriot, AstraZeneca CEO. Previously, Dunoyer was Global Head of Rare Diseases at GlaxoSmithKline, where, he established an integrated global capability in treatments for rare diseases from R&D through to commercialization. While at GlaxoSmithKline, he served as President, Pharmaceuticals Japan from 2000 until 2008 and President, Pharmaceuticals Asia Pacific/Japan from 2008 to 2010.
The newly created American Association for Cancer Research (AACR) Academy selected Angela H. Brodie, Ph.D, as a fellow. Brodie is professor of pharmacology at the University of Maryland School of Medicine and scientist at the U. of Maryland Marlene and Stewart Greenebaum Cancer Center. She pioneered a class of drugs called aromatase inhibitors, which are used to help prevent recurrence of breast cancer in postmenopausal women.
Richard W. Pascoe was appointed Chief Executive Officer of Apricus Biosciences. Previously, Pascoe served as CEO and President of Somaxon Pharmaceuticals. Earlier he was the COO at ARIAD Pharmaceuticals, an emerging oncology company. He also held a series of senior management roles at King Pharmaceuticals, Inc., including senior vice president of neuroscience marketing and sales.
AssureRx Health named Stephen A. Stamp Senior Vice President & Chief Financial Officer and Jeffrey P. Bush VP, Payer Markets and Reimbursement. Stamp has served as Chief Financial Officer of EZCORP, a consumer financial services company; COO, CFO, and Executive VP at Xanodyne Pharmaceuticals; and Group Finance Director at Shire Pharmaceuticals. Bush previously was senior director of Reimbursement Strategy & Payment Policy at Becton Dickinson, where he managed reimbursement worldwide and was instrumental in the development and passage of reform legislation concerning coverage and payment for new diagnostic technologies.
Avaxia Biologics appointed Deborah S. Hartman, Ph.D., as Vice President, Research. Before joining Avaxia, Dr. Hartman held a number of executive-level roles at AstraZeneca, most recently as VP of Projects in Innovative Medicines. Earlier Hartman spent seven years at Hoffmann-La Roche in Basel, Switzerland, as a Project Leader and Principal Scientist in nervous system diseases.
BD (Becton Dickinson) named Ellen Strahlman, M.D., to the newly created position of Chief Medical Officer and Senior VP, Research & Development. Strahlman previously served at GlaxoSmithKline as Senior VP and Chief Medical Officer and most recently Senior Medical Advisor and Global Head of Neglected Tropical Diseases. She was responsible for Vaccines, Pharmaceutical and Consumer businesses, as well as medical affairs, regulatory affairs, clinical safety and other areas. Prior to GlaxoSmithKline, she held executive leadership roles at Merck, Novartis, Pfizer and Bausch & Lomb.
Roger M. Perlmutter, M.D., Ph.D., was named Executive VP and President of Merck Research Laboratories. Perlmutter was previously Executive Vice President and head of R&D at Amgen for 11 years, where he oversaw development of several novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis. Earlier he was Executive Vice President of Worldwide Basic Research and Preclinical Development at Merck.
PDI and Group DCA
JoAnn Saitta, Chief Information Officer at PDI and General Manager at Group DCA, became the first woman to receive the CIO of the Year Award from the New Jersey Technology Council since its founding in 2005. Saitta manages the technology strategy of PDI in addition to leading the transformation of Group DCA, a PDI company. In this capacity, Saitta has led the creation of a blueprint for a single healthcare practitioner customer master from multiple sources within a company to advance business intelligence from “Big Data” analytics.
The nonprofit Sansum Diabetes Research Insitute named Rem Laan Executive Director. He will be responsible for strategic planning, operations, major gift development and donor cultivation. Laan comes to Sansum from Roche Diagnostics, where he spent more than 10 years in increasingly responsible positions culminating in his role as Vice President for External Affairs for North American Diabetes Care. Previously, he was the Director of Marketing for Disetronic Medical Systems, a Swiss insulin pump manufacturer.
Lee F. Allen, M.D., Ph.D., was appointed Chief Medical Officer at Spectrum Pharmaceuticals, a biotech company focusing primarily on hematology and oncology. Allen will lead the clinical development of Spectrum’s product pipeline. He was previously Chief Medical Officer and Executive VP at AMAG Pharmaceuticals. Earlier, he held senior leadership roles at Wyeth, Pfizer, and BASF’s Knoll Pharmaceuticals. Allen also has over 10 years of extensive research experience and more than 40 papers published.